MDT-AP-1136
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 24
- os_event
- false
- age_years
- 8
- sex
- M
- new_clusters
- C5
- umap1_2d
- 6.098222468
- umap2_2d
- 4.84331747
- umap1_3d
- 3.395466023
- umap2_3d
- -1.278793372
- umap3_3d
- -2.646492606
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.190
- KRAS_SIGNALING_DN+0.150
- DNA_REPAIR+0.100
- SPERMATOGENESIS+0.100
- HEME_METABOLISM+0.040
- PI3K_AKT_MTOR_SIGNALING+0.030
- APICAL_SURFACE-0.040
- PEROXISOME-0.070
- APICAL_JUNCTION-0.080
- MITOTIC_SPINDLE-0.080
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- TNFA_SIGNALING_VIA_NFKB-0.490
- INTERFERON_ALPHA_RESPONSE-0.440
- APOPTOSIS-0.410
- ANGIOGENESIS-0.360
- INTERFERON_GAMMA_RESPONSE-0.360
- OXIDATIVE_PHOSPHORYLATION-0.360
- IL6_JAK_STAT3_SIGNALING-0.350
- MYC_TARGETS_V1-0.350
- INFLAMMATORY_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1436444 | GTEX | — | 0.934 |
| 2 | SRR1433644 | GTEX | — | 0.930 |
| 3 | SRR1478096 | GTEX | — | 0.929 |
| 4 | SRR1364800 | GTEX | — | 0.927 |
| 5 | SRR1434271 | GTEX | — | 0.924 |
| 6 | SRR1338669 | GTEX | — | 0.924 |
| 7 | SRR1377984 | GTEX | — | 0.923 |
| 8 | SRR1341605 | GTEX | — | 0.923 |
| 9 | MDT-AP-1160 | Med | Medulloblastoma | 0.922 |
| 10 | SRR1467813 | GTEX | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |